B-MS hails new 'landmark' Opdivo data

Bristol-Myers Squibb’s (NYSE: BMY) week started on a high note as the latest data on its immune-oncology asset Opdivo (nivolumab) sent the company’s share price up by 1% to $54.88 in the first hour of trading.

The US pharma major presented new long-term survival data for the drug during the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington DC, USA.

In the Phase Ib single arm trial, primarily looking at safety and tolerability across different doses, nearly 16 of 129 patients with previously-treated, advanced non-small cell lung cancer (NSCLC) were still alive at five-years. Typically, five-year survival in advanced lung cancer is just 1%.